Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
earnings-consensus: Archive
Does Upwork (UPWK) Have the Potential to Rally 45.37% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 45.4% in Upwork (UPWK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
UPWKNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in Offerpad Solutions (OPAD)? Wall Street Analysts Think 25.76%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Offerpad Solutions (OPAD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
OPADPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 96.5% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
AUPHPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 34.34% Upside in Workiva (WK): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Workiva (WK) points to a 34.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
WKNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 36.09% Upside in Castle Biosciences (CSTL): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Castle Biosciences (CSTL) points to a 36.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CSTLNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in The Bancorp (TBBK)? Wall Street Analysts Think 45.56%
by Zacks Equity Research
The consensus price target hints at a 45.6% upside potential for The Bancorp (TBBK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
TBBKPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe PowerFleet (PWFL) Could Rally 61.8%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for PowerFleet (PWFL) points to a 61.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
PWFLNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Shattuck Labs (STTK) Have the Potential to Rally 34.17% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 34.2% in Shattuck Labs (STTK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
STTKNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think SOPHiA GENETICS (SOPH) Could Surge 64.95%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 65% in SOPHiA GENETICS (SOPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SOPHNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Analysts Estimate Paysafe Limited (PSFE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Paysafe Limited (PSFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PSFEPositive Net Change FOURNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Will Hyperfine, Inc. (HYPR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Hyperfine (HYPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HYPRPositive Net Change LFWDPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Will Akoustis (AKTS) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Akoustis (AKTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AKTSNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Xencor (XNCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Xencor (XNCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
XNCRNegative Net Change FENCNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Analysts Estimate Intercorp Financial Services Inc. (IFS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Intercorp Financial Services (IFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IFSPositive Net Change FPAYPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AKYAPositive Net Change IGMSNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Analysts Estimate Bitfarms Ltd. (BITF) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bitfarms (BITF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BITFNegative Net Change AMPXPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Shockwave Medical (SWAV) Earnings Expected to Grow: What to Know Ahead of Q1 Release
by Zacks Equity Research
Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SWAVPositive Net Change STENegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Wall Street Analysts See a 77.22% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 77.2% in Bicycle Therapeutics (BCYC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BCYCPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 38.7% upside potential for Tarsus Pharmaceuticals (TARS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
TARSNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 56.11% Upside in Pulmonx (LUNG): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 56.1% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
LUNGNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Enbridge (ENB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Enbridge (ENB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ENBPositive Net Change PBAPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Will Construction Partners (ROAD) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Construction Partners (ROAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ROADNegative Net Change JBINo Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Earnings Preview: Crescent Point Energy (CPG) Q1 Earnings Expected to Decline
by Zacks Equity Research
Crescent Point (CPG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CPGNegative Net Change OVVNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Gain Therapeutics (GANX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GANXNegative Net Change OPTNPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
AMC Networks (AMCX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
AMC Networks (AMCX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMCXPositive Net Change WBDPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate